Sweden
· Delayed Price · Currency is SEK BINV Statistics
Total Valuation
BioInvent International AB has a market cap or net worth of SEK 3.00 billion. The enterprise value is 2.07 billion.
| Market Cap | 3.00B |
| Enterprise Value | 2.07B |
Important Dates
The last earnings date was Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioInvent International AB has 65.80 million shares outstanding. The number of shares has increased by 0.96% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 65.80M |
| Shares Change (YoY) | +0.96% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.83% |
| Owned by Institutions (%) | 18.28% |
| Float | 32.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 77.81 |
| PB Ratio | 2.99 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.06 |
| EV / Sales | 53.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.65 |
Financial Position
The company has a current ratio of 13.29, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.29 |
| Quick Ratio | 13.16 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -715.88 |
Financial Efficiency
Return on equity (ROE) is -34.01% and return on invested capital (ROIC) is -23.33%.
| Return on Equity (ROE) | -34.01% |
| Return on Assets (ROA) | -22.21% |
| Return on Capital (ROIC) | -23.33% |
| Revenue Per Employee | 335,965 |
| Profits Per Employee | -3.56M |
| Employee Count | 111 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +204.28% in the last 52 weeks. The beta is 0.33, so BioInvent International AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +204.28% |
| 50-Day Moving Average | 44.99 |
| 200-Day Moving Average | 33.22 |
| Relative Strength Index (RSI) | 48.57 |
| Average Volume (20 Days) | 76,761 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioInvent International AB had revenue of SEK 38.64 million and -409.65 million in losses. Loss per share was -6.22.
| Revenue | 38.64M |
| Gross Profit | 38.64M |
| Operating Income | -456.73M |
| Pretax Income | -409.36M |
| Net Income | -409.65M |
| EBITDA | -445.24M |
| EBIT | -456.73M |
| Loss Per Share | -6.22 |
Balance Sheet
The company has 950.11 million in cash and 17.02 million in debt, giving a net cash position of 933.09 million or 14.18 per share.
| Cash & Cash Equivalents | 950.11M |
| Total Debt | 17.02M |
| Net Cash | 933.09M |
| Net Cash Per Share | 14.18 |
| Equity (Book Value) | 1.00B |
| Book Value Per Share | 15.24 |
| Working Capital | 934.92M |
Cash Flow
In the last 12 months, operating cash flow was -354.55 million and capital expenditures -11.94 million, giving a free cash flow of -366.49 million.
| Operating Cash Flow | -354.55M |
| Capital Expenditures | -11.94M |
| Free Cash Flow | -366.49M |
| FCF Per Share | -5.57 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,182.13% |
| Pretax Margin | -1,059.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -948.57% |
Dividends & Yields
BioInvent International AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.96% |
| Shareholder Yield | -0.96% |
| Earnings Yield | -13.63% |
| FCF Yield | -12.20% |
Stock Splits
The last stock split was on December 14, 2020. It was a reverse split with a ratio of 0.04.
| Last Split Date | Dec 14, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |